Loading...
XPAR
VETO
Market cap973mUSD
May 23, Last price  
72.60EUR
1D
-1.49%
1Q
-0.82%
Jan 2017
59.46%
IPO
215.65%
Name

Vétoquinol

Chart & Performance

D1W1MN
P/E
15.42
P/S
1.62
EPS
4.71
Div Yield, %
1.17%
Shrs. gr., 5y
-0.01%
Rev. gr., 5y
7.54%
Revenues
529m
-1.95%
196,617,000211,591,000233,364,000234,395,000257,057,000282,041,000284,137,000298,293,000299,727,000315,298,000342,612,000350,354,000352,173,000367,941,000395,990,000427,467,000521,272,000539,779,000529,270,999
Net income
56m
+15.76%
12,440,72015,824,00018,642,00018,564,00018,207,00022,255,00022,695,00022,569,00023,580,00025,766,00024,156,00027,827,00034,831,00036,259,00028,589,00019,221,00062,861,00047,995,00055,560,000
CFO
89m
+43.27%
30,014,00023,356,00037,215,00021,903,00040,046,00034,360,00029,992,00034,209,00028,106,00041,298,00038,897,00043,205,00041,225,00037,884,00052,024,00092,012,00089,167,00062,392,00089,391,000
Dividend
Jun 04, 20240.85 EUR/sh
Earnings
Sep 10, 2025

Profile

Vetoquinol SA, a veterinary pharmaceutical company, designs, develops, and sells veterinary drugs and non-medicinal products in Europe, the Americas, and the Asia Pacific region. It provides products in the areas of mobility, pain, and inflammation; dermatology, hygiene, and care; anti-parasite; udder health; infectious diseases; reproduction; behavior management; internal medicine; and cardiology-nephrology for cattle, sheep, pigs, poultry, and dogs. The company was founded in 1933 and is headquartered in Lure, France. Vetoquinol SA is a subsidiary of Soparfin SCA.
URL
https://www.vetoquinol.com/fr
IPO date
Nov 16, 2006
Employees
2,455
Domiciled in
FR
Incorporated in
FR

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
529,271
-1.95%
539,779
3.55%
Cost of revenue
460,546
487,931
Unusual Expense (Income)
NOPBT
68,725
51,848
NOPBT Margin
12.98%
9.61%
Operating Taxes
21,340
20,649
Tax Rate
31.05%
39.83%
NOPAT
47,385
31,199
Net income
55,560
15.76%
47,995
-23.65%
Dividends
(9,465)
(9,465)
Dividend yield
0.78%
0.91%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
7,965
7,860
Long-term debt
24,132
9,561
Deferred revenue
9,382
Other long-term liabilities
8,901
9,220
Net debt
(116,858)
(77,731)
Cash flow
Cash from operating activities
89,391
62,392
CAPEX
(14,896)
(22,497)
Cash from investing activities
(18,881)
(21,518)
Cash from financing activities
(15,497)
(15,600)
FCF
(2,705)
(6,598)
Balance
Cash
147,464
93,708
Long term investments
1,491
1,444
Excess cash
122,491
68,163
Stockholders' equity
485,984
491,532
Invested Capital
431,148
437,563
ROIC
10.91%
7.31%
ROCE
12.25%
10.09%
EV
Common stock shares outstanding
11,833
11,832
Price
102.40
16.89%
87.60
-33.64%
Market cap
1,211,649
16.90%
1,036,447
-33.61%
EV
1,094,888
958,808
EBITDA
103,227
83,398
EV/EBITDA
10.61
11.50
Interest
1,137
3,261
Interest/NOPBT
1.65%
6.29%